Cancer treatment using peptides: current therapies and future prospects
Jyothi Thundimadathil. J Amino Acids. 2012.
Abstract
This paper discusses the role of peptides in cancer therapy with special emphasis on peptide drugs which are already approved and those in clinical trials. The potential of peptides in cancer treatment is evident from a variety of different strategies that are available to address the progression of tumor growth and propagation of the disease. Use of peptides that can directly target cancer cells without affecting normal cells (targeted therapy) is evolving as an alternate strategy to conventional chemotherapy. Peptide can be utilized directly as a cytotoxic agent through various mechanisms or can act as a carrier of cytotoxic agents and radioisotopes by specifically targeting cancer cells. Peptide-based hormonal therapy has been extensively studied and utilized for the treatment of breast and prostate cancers. Tremendous amount of clinical data is currently available attesting to the efficiency of peptide-based cancer vaccines. Combination therapy is emerging as an important strategy to achieve synergistic effects in fighting cancer as a single method alone may not be efficient enough to yield positive results. Combining immunotherapy with conventional therapies such as radiation and chemotherapy or combining an anticancer peptide with a nonpeptidic cytotoxic drug is an example of this emerging field.
PubMed Disclaimer
Figures Figure 1
Different possible treatment options of cancer using peptides. Peptides can be used as anticancer drug, cytotoxic drug carrier, vaccine, hormones, and radionuclide carrier. Figure 2
Peptide receptor radionuclide therapy (PRRT); radiolabeled somatostatin analogs generally comprise three main parts: a cyclic octapeptide (e.g., Tyr3-octreotide or Tyr3-octreotate), a chelator (e.g., DTPA or DOTA), and a radioactive element. Radioisotopes commonly used in PRRT are 111In, 90Y, and 177Lu. Figure 3
Peptide-based cancer vaccines: tumor cells express antigens known as tumor-associated antigens (TAAs) that can be recognized by the host's immune system (a). These TAAs mixed with an adjuvant can be injected into cancer patients in an attempt to induce a systemic immune response (b). The antigen presenting cell (APC) presents the antigen to T cell ((c) and (d)), thereby the T cell is activated (e) which results in the destruction of the cancer cell (f).
References
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer Journal for Clinicians. 2011;61(2):69–90. - PubMed
Global cancer facts & figures. 2nd edition, American Cancer Society, http://www.cancer.org/
Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nature Medicine. 2004;10(8):789–799. - PubMed
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine. 1995;1(1):27–31. - PubMed
Kakde D, Jain D, Shrivastava V, Kakde R, Patil AT. Cancer therapeutics—opportunities, challenges and advances in drug delivery. Journal of Applied Pharmaceutical Science. 2011;1(9):1–10.